Core Insights - TREOS Bio Ltd. has entered into clinical collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences to initiate the OBERTO-202 Phase II clinical trial, evaluating PolyPEPI1018 in combination with toripalimab for treating microsatellite stable metastatic colorectal cancer [1][2] - The company has successfully completed a $2.1 million bridge financing, raising the total financing to $47 million, excluding non-dilutive support [1] Company Overview - TREOS Bio is a clinical-stage biotechnology company focused on developing precision cancer immunotherapies using its proprietary PASCal platform [5] - The lead program, PolyPEPI1018, is designed to target shared tumor antigens and has shown clinical activity in advanced microsatellite stable colorectal cancer [5] Clinical Trial Details - The OBERTO-202 study will be conducted at Charité – Universitätsmedizin Berlin, involving 14 leading academic hospitals and approximately 140 patients with relapsed/refractory microsatellite stable colorectal cancer [2] - The trial will compare the combination of PolyPEPI1018 and toripalimab with standard care (Lonsurf + Avastin) against standard care alone [2] Market Context - Microsatellite stable colorectal cancer accounts for about 85% of all colorectal cancer cases, affecting an estimated 130,000 new patients annually in the US and over 1.6 million globally [4] - Current immunotherapies have shown limited efficacy in this patient population, indicating a significant unmet medical need [4] Leadership Insights - The collaboration with Charité Berlin and Junshi Biosciences is viewed as a significant milestone in demonstrating the potential of TREOS Bio's precision immunotherapy approach [3] - The randomized controlled trial is seen as a logical next step in the development of PolyPEPI1018, aiming to overcome resistance to immunotherapies in microsatellite stable colorectal cancer [3]